Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 6/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 4/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.39 |
| ▸ | PLG | P00747 | 2/20 | 0.39 |
| ▸ | PLAT | P00750 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440953 | 0.94 | SIRT2 (0.46) | HSD17B2SIRT2LIMK2PLAUHSD17B1 | |
| SCHEMBL5360569 | 0.94 | SIRT2 (0.44) | HSD17B2SIRT2LIMK2PLAUHSD17B1 | |
| SCHEMBL5355385 | 0.88 | AOC3 (0.45) | HSD17B2SIRT2HTTPOLBAOC3 | |
| SCHEMBL5374247 | 0.87 | SMO (0.42) | HSD17B2SIRT2AOC3 | |
| SCHEMBL5360945 | 0.86 | HSD17B2 (0.37) | HSD17B2SIRT2LIMK2HSD17B1 | |
| SCHEMBL6268147 | 0.85 | MEN1 (0.44) | HSD17B2SIRT2MAPT | |
| SCHEMBL5361805 | 0.85 | PLAU (0.39) | SIRT2PLAUPLGPLATMAPT | |
| SCHEMBL5358809 | 0.85 | NR1H4 (0.45) | HSD17B2SIRT2LIMK2PLAUHSD17B1 | |
| SCHEMBL5359865 | 0.84 | HSD17B2 (0.52) | HSD17B2HSD17B1HTTABHD6POLB | |
| SCHEMBL5365912 | 0.84 | HSD17B2 (0.44) | HSD17B2LIMK2PLAUHSD17B1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572629-A1 | COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-14 | — | — | EP | claimed |
| WO-2004052840-A1 | COMPOUNDS WHICH MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-24 | — | — | WO | claimed |
| US-7307078-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-11 | — | — | US | disclosed |
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-04-26 | — | — | US | disclosed |
| US-7125869-B2 | Polycyclic compounds which modulate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-10-24 | — | — | US | disclosed |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-01-12 | — | — | US | disclosed |
| EP-1572629-A1 | COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development, S.N.C. (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052840-A1 | COMPOUNDS WHICH MODULATE PPARϜ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093487-A1 | 2-[3'-({[6-(2-Methoxyethoxymethoxy)naphthalene-2-carbonyl]methylamino}methyl)biphenyl-4-ylamino]methyl benzoate; dermatology, cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism, cosmetics | MITF, AHR, PAH | HSD17B2 579/4885SIRT2 452/4885LIMK2 2657/4885 |
| US-20060009484-A1 | Novel polycyclic compounds which modulate PPARgamma type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | HSD17B2 648/4885SIRT2 751/4885LIMK2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.